Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20385344 | 1.00 | GAA (0.39) | GAAL3MBTL1IDO1ALDH1A1GLA | |
| SCHEMBL28046490 | 0.85 | IDO1 (0.48) | GAAL3MBTL1IDO1ALDH1A1CYP2D6 | |
| SCHEMBL10405701 | 0.85 | IDO1 (0.48) | GAAL3MBTL1IDO1ALDH1A1CYP2D6 | |
| SCHEMBL22863464 | 0.82 | GAA (0.38) | GAAL3MBTL1IDO1ALDH1A1GLA | |
| SCHEMBL22863229 | 0.82 | GAA (0.38) | GAAL3MBTL1IDO1ALDH1A1GLA | |
| SCHEMBL22863305 | 0.82 | GAA (0.38) | GAAL3MBTL1IDO1ALDH1A1GLA | |
| SCHEMBL29054036 | 0.81 | GAA (0.52) | GAAL3MBTL1IDO1ALDH1A1CYP2D6 | |
| SCHEMBL7823538 | 0.81 | GAA (0.57) | GAAL3MBTL1IDO1ALDH1A1MCOLN3 | |
| SCHEMBL21949437 | 0.81 | SLC6A2 (0.36) | GAAALDH1A1CSF1RCYP3A4 | |
| SCHEMBL18239303 | 0.81 | KDM4E (0.39) | IDO1ALDH1A1CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3294739-B1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-31 | — | — | EP | disclosed |
| US-9725449-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160333013-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-17 | — | — | US | disclosed |
| WO-2016183118-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333013-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MCL1, TP53, TOP2A | GAA 218/4885L3MBTL1 2418/4885IDO1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.